Clinical Trials on Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8

Total 550 results

Rahul Aggarwal
Merck Sharp & Dohme LLC; U.S. Army Medical Research and Development Command; Zenith...

Recruiting

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Metastatic Prostate Small Cell Carcinoma

United States
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

Kidney Cancer | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Refractory Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8

United States
Emory University
National Cancer Institute (NCI)

Active, not recruiting

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Advanced Pancreatic Adenocarcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
University of California, Davis
Bristol-Myers Squibb; National Cancer Institute (NCI); Dynavax Technologies Corporation

Completed

SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Refractory Pancreatic Adenocarcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)

Metastatic Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Unresectable Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

Metastatic Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Unresectable Renal Cell Carcinoma | TFE3-Rearranged Renal Cell Carcinoma

United States, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Emory University
National Cancer Institute (NCI); Novartis; National Institutes of Health (NIH); EUSA Pharma, Inc...

Completed

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IIA Cervical Cancer AJCC v7 | Stage IB Cervical Cancer AJCC v6 and v7 | Stage I Cervical Cancer AJCC v6 and v7 | Stage IA Cervical Cancer AJCC v6 and v7

United States, Korea, Republic of, Japan
University of Southern California
National Cancer Institute (NCI); Auransa, Inc.

Recruiting

AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Advanced Hepatocellular Carcinoma | Metastatic Malignant Neoplasm in the Liver | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Advanced Cholangiocarcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Intraductal Papillary-Mucinous Neoplasm | Stage I Pancreatic Cancer AJCC v6 and v7 | Stage II Pancreatic Cancer AJCC v6 and v7

United States, Canada, Israel, Belgium
Mayo Clinic

Recruiting

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

Gastric Adenocarcinoma | Clinical Stage IV Gastric Cancer AJCC v8 | Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Carcinoma | Metastatic Malignant Neoplasm in the Peritoneum

United States
M.D. Anderson Cancer Center

Active, not recruiting

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

Pancreatic Ductal Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | KRAS NP_004976.2:p.G12D

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer

Stage I Uterine Corpus Cancer AJCC v8

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study

Anatomic Stage 0 Breast Cancer AJCC v8 | Prognostic Stage 0 Breast Cancer AJCC v8 | Breast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Bilateral Breast Carcinoma

United States
Rashmi Verma, MD
National Cancer Institute (NCI)

Recruiting

Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
National Cancer Institute (NCI)

Recruiting

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Metastatic Merkel Cell Carcinoma | Metastatic Skin Squamous Cell Carcinoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Basal Cell Carcinoma | Unresectable Merkel Cell Carcinoma | Unresectable... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Anne Noonan
National Cancer Institute (NCI)

Recruiting

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Astellas Pharma Inc; Seagen...

Recruiting

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Stage III Bladder Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Metastatic Bladder Carcinoma | Urachal Adenocarcinoma | Locally Advanced Bladder Carcinoma | Malignant Renal Pelvis Neoplasm | Malignant Ureter Neoplasm | Malignant Urethral Neoplasm and other conditions

United States
Emory University
National Cancer Institute (NCI); Prostate Cancer Foundation

Recruiting

Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy

Prostate Adenocarcinoma | Stage IIB Prostate Cancer AJCC v8

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer (NRG PROMETHEAN)

Prostate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial... and other conditions

United States, Korea, Republic of, Canada, Puerto Rico, Japan
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Terminated

Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

Clear Cell Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Unresectable Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v7

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Recruiting

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer

Refractory Malignant Solid Neoplasm | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer

Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Advanced Renal Cell Carcinoma | Unresectable Renal Cell Carcinoma

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery

Clear Cell Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Recurrent Clear Cell Renal Cell Carcinoma

United States
University of Washington
Novartis; Institute for Prostate Cancer Research (IPCR)

Not yet recruiting

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Mayo Clinic

Recruiting

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Jonsson Comprehensive Cancer Center
POINT Biopharma

Active, not recruiting

177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study (LUNAR)

Prostate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma | Recurrent Prostate Adenocarcinoma

United States
Fred Hutchinson Cancer Center
PromiCell Therapeutics, Inc.

Not yet recruiting

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
University of Washington
National Cancer Institute (NCI)

Recruiting

Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
M.D. Anderson Cancer Center

Recruiting

Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Lung Adenocarcinoma | Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8

United States
Fred Hutchinson Cancer Center
Bristol-Myers Squibb

Not yet recruiting

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage III Prostate Cancer AJCC v8 | Prostate Small Cell Neuroendocrine Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

Metastatic Merkel Cell Carcinoma | Refractory Merkel Cell Carcinoma | Locally Advanced Merkel Cell Carcinoma | Unresectable Merkel Cell Carcinoma | Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Locally Advanced Malignant Solid Neoplasm | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Locally Advanced Clear Cell Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Mucosal Melanoma | Anal Melanoma | Bladder Melanoma | Cervical Melanoma | Esophageal Melanoma | Gallbladder Melanoma | Mucosal Melanoma of the Head and Neck | Mucosal Melanoma of the Urinary System | Oral Cavity Mucosal Melanoma | Penile Mucosal Melanoma | Rectal Melanoma | Recurrent Mucosal Melanoma | Sinonasal... and other conditions

United States, Canada
Emory University
National Cancer Institute (NCI)

Recruiting

Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Oropharyngeal HPV-Positive Squamous Cell Carcinoma

United States
M.D. Anderson Cancer Center

Withdrawn

Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study

Lung Non-Small Cell Carcinoma | Stage I Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Lung

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm

United States

Clinical Trials on Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations